All In Biotech

Drug Trial Radar · NCT06475599

Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Efficacy of Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer in a Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Jul 2024

Primary completion

Dec 2027

Study completion Jun 2029

Sponsor

Sponsor type
Industry
First posted
Jun 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate that anlotinib hydrochloride capsules combined with TQB2450 injection can significantly prolong progression-free survival (PFS) compared with chemotherapy in patients with recurrent or metastatic endometrial cancer that is non- microsatellite instability high (non-MSI-H) or DNA mismatch repair deficient (non-dMMR).

Conditions

  • Endometrial Cancer

Interventions

  • Anlotinib hydrochloride capsule + TQB2450 injectionDrug

    Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time. TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response.

  • Chemotherapy drugDrug

    Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by independent imaging review committee (IRC)Time frame: Up to 36 months after study start

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University

    Beijing, China

  • Beijing Chaoyang Hospital, Capital Medical University

    Beijing, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • The Southwest Hospital of Amu

    Chongqing, China

  • Chongqing University Three Gorges Hospital

    Chongqing, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • The Affiliated Hospital of Southwest Medical University

    Chongqing, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Shanghai Tenth People's Hospital

    Shanghai, China

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China

  • Tianjin Central Hospital of Gynecology Obstetrics

    Tianjin, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • Huizhou Central People's Hospital

    Huizhou, Guangdong, China

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China

  • Meizhou People's Hospital

    Meizhou, Guangdong, China

  • Guigang City People's Hospital

    Guigang, Guangxi, China

  • Nanxishan Hospital of Guangxi Zhuang Autonomous Region

    Guilin, Guangxi, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • Liuzhou Municipal Liutie Central Hospital

    Liuzhou, Guangxi, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • Hainan Ceneral Hospital

    Haikou, Hainan, China

  • Tangshan People's Hospital

    Tangshan, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Nanyang first People's Hospital National Third Class A Hospital

    Nanyang, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The Central Hospital Of Shaoyang

    Shaoyang, Hunan, China

  • Inner Mongolia Autonomous Region People's Hospital

    Hohhot, Inner Mongolia, China

  • Changchun Tumor Hospital

    Changchun, Jilin, China

  • The first hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Shengjing Hospital Of China Medical University

    Shenyang, Liaoning, China

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.